Acute decompensated heart failure: Contemporary medical management

Texas Heart Institute Journal

Volumn 36, Issue 6, 2009, Pages 510-520

  Joseph, Susan M ^a   Cedars, Ari M ^a   Ewald, Gregory A ^a   Geltman, Edward M ^a   Mann, Douglas L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute disease; Aged; Cardiac output, low; Disease progression; Diuretics; Furosemide; Heart failure classification drug therapy mortality; Hospitalization; Length of stay; Milrinone; Morbidity trends; Relaxin; Tolvaptan; Ultrafiltration; United states epidemiology; Vasodilator agents; Ventricular dysfunction, left

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; CONIVAPTAN; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INDOMETACIN; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; NAXIFYLLINE; NESIRITIDE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RELAXIN; ROLOFYLLINE; SPIRONOLACTONE; TOLVAPTAN; TORASEMIDE; URODILATIN; VASODILATOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DIURETIC THERAPY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FORWARD HEART FAILURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPONATREMIA; HYPOTENSION; LIVER FUNCTION; LIVER PERFUSION; LOADING DRUG DOSE; LUNG EDEMA; MORBIDITY; NOMENCLATURE; OTOTOXICITY; PATIENT MONITORING; REVIEW; SIDE EFFECT; SYMPTOM; TELEMETRY; TREATMENT RESPONSE; ULTRAFILTRATION; VALVULAR HEART DISEASE; VASODILATATION;

ACUTE DISEASE; AGED; CARDIOTONIC AGENTS; CARDIOVASCULAR AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HEMOFILTRATION; HOSPITALIZATION; HUMANS; MALE; MONITORING, PHYSIOLOGIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 76149106490     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52(6):428-34.
2. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005;96(6A): 5G-10G.
3. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell'italia LJ, et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 2008;14(3):211-8.
4. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116(13):1482-7.
5. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112(25): 3958-68.
6. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11(3):200-5.
7. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27(22):2725-36.
8. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW; ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007;153(6): 1021-8.
9. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296(18):2217-26.
10. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13(6):422-30.
11. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database [published erratum appears in J Am Coll Cardiol 2006;47(7):1502]. J Am Coll Cardiol 2006;47 (1):76-84.
12. Opasich C, Rapezzi C, Lucci D, Gorini M, Pozzar F, Zanelli E, et al. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol 2001;88(4):382-7.
13. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008;168(8):847-54.
14. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149 (2):209-16.
15. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26(4):384-416.
16. Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002;4(3):227-34.
17. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41(10):1797-804.
18. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006;12(1):e86-e103.
19. Peacock WF 4th, Fonarow GC, Emerman CL, Mills RM, Wynne J; ADHERE Scientific Advisory Committee and Investigators; Adhere Study Group. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology 2007;107(1):44-51.
20. Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, Mills RM. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;52(7):534-40.
21. Perloff JK, Roberts WC. The mitral apparatus. Functional anatomy of mitral regurgitation. Circulation 1972;46(2):227-39.
22. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8(3):136-41.
23. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9 (10):1064-9.
24. Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly. Chest 2001;119(3):807-10.
25. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973;288(21):1087-90.
26. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43(11):2028-35.
27. Lopez B, Querejeta R, Gonzalez A, Beaumont J, Larman M, Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009;53(2):236-42.
28. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006;92 (10):1434-40.
29. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study [published erratum appears in Eur J Heart Fail 2002;4(5):667]. Eur J Heart Fail 2002;4(4):507-13.
30. Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of publications. Br Med J 1980;280(6218):905-8.
31. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25(5):563-75.
32. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341 (10):709-17.
33. Gottlieb SS, Robinson S, Krichten CM, Fisher ML. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992;70(9):890-3.
34. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;52(3):190-9.
35. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2004;(1): CD003178.
36. Kiyingi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;335(8680):29-31.
37. Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46(11):2043-6.
38. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure [published erratum appears in J Am Coll Cardiol 2007;49(10):1136]. J Am Coll Cardiol 2007;49(6):675-83.
39. Liang KV, Hiniker AR, Williams AW, Karon BL, Greene EL, Redfield MM. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail 2006; 12(9):707-14.
40. Rogers HL, Marshall J, Bock J, Dowling TC, Feller E, Robinson S, Gottlieb SS. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail 2008;14 (1):1-5.
41. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287(12):1541-7.
42. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112.
43. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319-31.
44. Finley JJ 4th, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia [published erratum appears in Circulation 2008;119 (21):e552]. Circulation 2008;118(4):410-21.
45. Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14(8):641-7.
46. Conrad KP, Novak J. Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 2004;287(2):R250-61.
47. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15(3):182-90.
48. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373(9673):1429-39.
49. Edlund A, Ohlsen H, Sollevi A. Renal effects of local infusion of adenosine in man. Clin Sci (Lond) 1994;87(2):143-9.
50. Marraccini P, Fedele S, Marzilli M, Orsini E, Dukic G, Serasini L, L'Abbate A. Adenosine-induced renal vasoconstriction in man. Cardiovasc Res 1996;32(5):949-53.
51. deGoma EM, Vagelos RH, Fowler MB, Ashley EA. Emerging therapies for the management of decompensated heart failure: from bench to bedside. J Am Coll Cardiol 2006;48(12):2397-409.
52. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy [published erratum appears in Circulation 2002;106(13):1743]. Circulation 2002; 105(11):1348-53.
53. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008;14(8):631-40.
54. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27(23):2823-32.
55. Luss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS, et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008;155(6):1012. e1-8.
56. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360(9328):196-202.
57. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297(17):1883-91.